Literature DB >> 23749632

HLA peptide length preferences control CD8+ T cell responses.

Melissa J Rist1, Alex Theodossis, Nathan P Croft, Michelle A Neller, Andrew Welland, Zhenjun Chen, Lucy C Sullivan, Jacqueline M Burrows, John J Miles, Rebekah M Brennan, Stephanie Gras, Rajiv Khanna, Andrew G Brooks, James McCluskey, Anthony W Purcell, Jamie Rossjohn, Scott R Burrows.   

Abstract

Class I HLAs generally present peptides of 8-10 aa in length, although it is unclear whether peptide length preferences are affected by HLA polymorphism. In this study, we investigated the CD8(+) T cell response to the BZLF1 Ag of EBV, which includes overlapping sequences of different size that nevertheless conform to the binding motif of the large and abundant HLA-B*44 supertype. Whereas HLA-B*18:01(+) individuals responded strongly and exclusively to the octamer peptide (173)SELEIKRY(180), HLA-B*44:03(+) individuals responded to the atypically large dodecamer peptide (169)EECDSELEIKRY(180), which encompasses the octamer peptide. Moreover, the octamer peptide bound more stably to HLA-B*18:01 than did the dodecamer peptide, whereas, conversely, HLA-B*44:03 bound only the longer peptide. Furthermore, crystal structures of these viral peptide-HLA complexes showed that the Ag-binding cleft of HLA-B*18:01 was more ideally suited to bind shorter peptides, whereas HLA-B*44:03 exhibited characteristics that favored the presentation of longer peptides. Mass spectrometric identification of > 1000 naturally presented ligands revealed that HLA-B*18:01 was more biased toward presenting shorter peptides than was HLA-B*44:03. Collectively, these data highlight a mechanism through which polymorphism within an HLA class I supertype can diversify determinant selection and immune responses by varying peptide length preferences.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749632     DOI: 10.4049/jimmunol.1300292

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Naturally processed non-canonical HLA-A*02:01 presented peptides.

Authors:  Chopie Hassan; Eric Chabrol; Lorenz Jahn; Michel G D Kester; Arnoud H de Ru; Jan W Drijfhout; Jamie Rossjohn; J H Frederik Falkenburg; Mirjam H M Heemskerk; Stephanie Gras; Peter A van Veelen
Journal:  J Biol Chem       Date:  2014-12-12       Impact factor: 5.157

2.  Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy.

Authors:  Bracha Shraibman; Dganit Melamed Kadosh; Eilon Barnea; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2016-07-13       Impact factor: 5.911

Review 3.  Unmasking targets of antitumor immunity via high-throughput antigen profiling.

Authors:  Sebastiano Battaglia; Jason B Muhitch
Journal:  Curr Opin Biotechnol       Date:  2016-03-21       Impact factor: 9.740

4.  The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference.

Authors:  Thomas Trolle; Curtis P McMurtrey; John Sidney; Wilfried Bardet; Sean C Osborn; Thomas Kaever; Alessandro Sette; William H Hildebrand; Morten Nielsen; Bjoern Peters
Journal:  J Immunol       Date:  2016-01-18       Impact factor: 5.422

5.  T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Authors:  Melissa J Rist; Michelle A Neller; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

6.  Overlapping Peptides Elicit Distinct CD8+ T Cell Responses following Influenza A Virus Infection.

Authors:  Lisa M Assmus; Jing Guan; Ting Wu; Carine Farenc; Xavier Y X Sng; Pirooz Zareie; Angela Nguyen; Andrea T Nguyen; David C Tscharke; Paul G Thomas; Jamie Rossjohn; Stephanie Gras; Nathan P Croft; Anthony W Purcell; Nicole L La Gruta
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

Review 7.  Gene sharing between Epstein-Barr virus and human immune response genes.

Authors:  David H Dreyfus
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Authors:  Rachel J M Abbott; Laura L Quinn; Alison M Leese; Harry M Scholes; Annette Pachnio; Alan B Rickinson
Journal:  J Immunol       Date:  2013-10-21       Impact factor: 5.422

Review 9.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.

Authors:  Etienne Caron; Daniel J Kowalewski; Ching Chiek Koh; Theo Sturm; Heiko Schuster; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2015-12       Impact factor: 5.911

10.  Broad-Based Influenza-Specific CD8+ T Cell Response without the Typical Immunodominance Hierarchy and Its Potential Implication.

Authors:  Miaojuan Huang; Rong Xu; Cristina Triffon; Nicole Mifsud; Weisan Chen
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.